These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28473214)

  • 21. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.
    Xu Y; Pilla SJ; Alexander GC; Murimi IB
    PLoS One; 2019; 14(2):e0211820. PubMed ID: 30759121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.
    Coch RW; Green JB
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):767-72. PubMed ID: 27378397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescribing trends of glucose-lowering drugs in older adults from 2010 to 2021: A population-based study of Northern Italy.
    Foresta A; Succurro E; Baviera M; Macaluso G; Ojeda-Fernández L; Carla Roncaglioni M; Fortino I; Nobili A; Sesti G
    Diabetes Res Clin Pract; 2023 Aug; 202():110742. PubMed ID: 37270072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Outcome Trials with Glucose-Lowering Drugs.
    Thethi TK; Bilal A; Pratley RE
    Curr Cardiol Rep; 2021 Jun; 23(7):75. PubMed ID: 34081215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
    Patil HR; Al Badarin FJ; Al Shami HA; Bhatti SK; Lavie CJ; Bell DS; O'Keefe JH
    Am J Cardiol; 2012 Sep; 110(6):826-33. PubMed ID: 22703861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical use of GLP-1 agonists and DPP4 inhibitors.
    Tuch BE
    Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results from Cardiovascular Outcome Trials in Diabetes.
    Muñoz Torres M; Muñoz Garach A
    Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
    [No Abstract]   [Full Text] [Related]  

  • 34. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B
    J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.
    Wilcox T; De Block C; Schwartzbard AZ; Newman JD
    J Am Coll Cardiol; 2020 Apr; 75(16):1956-1974. PubMed ID: 32327107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review on cardiovascular effects of newer hypoglycaemic medications.
    Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
    Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study.
    Ena J; Carretero-Gómez J; Zapatero-Gaviria A; Carrasco-Sánchez FJ; Del Romero-Sánchez M; González-Becerra C; Blazquez-Encinar JC; Iguzquiza-Pellejero MJ; de Escalante Yangüela B; Gómez-Huelgas R;
    Rev Clin Esp (Barc); 2021 Nov; 221(9):517-528. PubMed ID: 34752263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.